low α- M1R positive allosteric modulator
7.5 mg+ PO QD in Ph. II for Parkinson’s
from eval. of M1R PAMs w/ low cooperativity
British Journal of Clinical Pharmacology
Takeda Pharmaceutical, Cambridge, USA
TAK-071
The Takeda brain-penetrant M1R positive allosteric modulator (PAM), TAK-071, was optimized for lower cooperativity (α) with the native ligand to theoretically reduce the side effect of diarrhea from M1R…